Source link : https://newshealth.biz/health-news/fda-expands-risankizumab-label-in-psoriatic-disease/
(MedPage Today) — The FDA expanded the indications for risankizumab (Skyrizi) in plaque psoriasis and psoriatic arthritis to include treatment of children 6 years and older, AbbVie announced. An interleukin (IL)-23 antagonist, risankizumab is… Source link : https://www.medpagetoday.com/dermatology/psoriasis/121968 Author : Publish date : 2026-06-29 16:53:00 Copyright for syndicated content belongs to the linked Source.
The post FDA Expands Risankizumab Label in Psoriatic Disease first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-29 16:53:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8